Edition:
India

ACADIA Pharmaceuticals Inc (ACAD.OQ)

ACAD.OQ on NASDAQ Stock Exchange Global Select Market

39.95USD
18 Oct 2019
Change (% chg)

$-0.03 (-0.08%)
Prev Close
$39.98
Open
$39.74
Day's High
$40.32
Day's Low
$39.38
Volume
1,719,733
Avg. Vol
631,470
52-wk High
$44.84
52-wk Low
$14.01

Latest Key Developments (Source: Significant Developments)

Acadia Pharma Says Pimavanserin Did Not Achieve Statistical Significance On Primary Endpoint
Tuesday, 23 Jul 2019 

July 22 (Reuters) - ACADIA Pharmaceuticals Inc ::ACADIA PHARMACEUTICALS ANNOUNCES TOP-LINE RESULTS FROM PHASE 3 ENHANCE TRIAL OF PIMAVANSERIN AS ADJUNCTIVE TREATMENT FOR PATIENTS WITH SCHIZOPHRENIA.ACADIA PHARMACEUTICALS INC - PIMAVANSERIN DID NOT ACHIEVE STATISTICAL SIGNIFICANCE ON PRIMARY ENDPOINT.ACADIA PHARMACEUTICALS INC - IN STUDY, SIGNIFICANT IMPROVEMENTS OBSERVED ON SECONDARY ENDPOINT OF PANSS NEGATIVE SYMPTOMS SCALE SUB-SCORE.  Full Article

Acadia Pharmaceuticals Says Co Submitted Update To Data Available Through Centers For Medicare And Medicaid Services Open Payments Database
Wednesday, 6 Mar 2019 

March 6 (Reuters) - ACADIA Pharmaceuticals Inc ::ACADIA PHARMACEUTICALS - ON MARCH 5, CO SUBMITTED UPDATE TO DATA AVAILABLE THROUGH CENTERS FOR MEDICARE AND MEDICAID SERVICES OPEN PAYMENTS DATABASE.ACADIA PHARMACEUTICALS - UPDATE IS TO RECLASSIFY CERTAIN CATEGORIZATION INFORMATION REGARDING GENERAL PAYMENTS PROVIDED TO PHYSICIANS.ACADIA PHARMACEUTICALS SAYS UPDATE WILL BE REFLECTED IN PUBLICLY AVAILABLE DATA POSTED ON OPENPAYMENTSDATA.CMS.GOV ON JUNE 30 - SEC FILING.  Full Article

Acadia Pharmaceuticals Reports Fourth Quarter Results
Wednesday, 27 Feb 2019 

Feb 26 (Reuters) - ACADIA Pharmaceuticals Inc ::ACADIA PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS.Q4 SALES $59.6 MILLION VERSUS REFINITIV IBES ESTIMATE OF $59.5 MILLION.Q4 LOSS PER SHARE $0.50.Q4 EARNINGS PER SHARE ESTIMATE $-0.55 -- REFINITIV IBES DATA.SEES 2019 NET SALES OF $275 MILLION TO $300 MILLION.ACADIA PHARMACEUTICALS - PLANS TO INITIATE TWO PHASE 3 TRIALS FOR PIMAVANSERIN AS ADJUNCTIVE TREATMENT FOR MDD IN FIRST HALF OF 2019.ACADIA PHARMACEUTICALS - AT DEC 31, 2018, CASH, CASH EQUIVALENTS, & INVESTMENT SECURITIES TOTALED $473.5 MILLION, COMPARED TO $341.3 MILLION AT DEC 31, 2017.NUPLAZID NET SALES ARE EXPECTED TO BE BETWEEN $275 MILLION AND $300 MILLION IN 2019.  Full Article

Acadia Pharmaceuticals Prices Public Offering Of Common Stock
Wednesday, 28 Nov 2018 

Nov 28 (Reuters) - ACADIA Pharmaceuticals Inc ::ACADIA PHARMACEUTICALS PRICES PUBLIC OFFERING OF COMMON STOCK.SAYS PUBLIC OFFERING OF 16.2 MILLION COMMON SHARES PRICED AT $17.00PER SHARE.GROSS PROCEEDS FROM OFFERING TO CO EXPECTED TO BE ABOUT $275.0 MILLION.OFFERING IS EXPECTED TO CLOSE ON NOVEMBER 30, 2018.  Full Article

Acadia Pharmaceuticals Files For Potential Stock Shelf Offering
Tuesday, 27 Nov 2018 

Nov 26 (Reuters) - ACADIA Pharmaceuticals Inc ::ACADIA PHARMACEUTICALS INC FILES FOR POTENTIAL STOCK SHELF OFFERING; SIZE NOT DISCLOSED .  Full Article

Acadia Announces Positive Top-Line Results From Phase 2 Pimavanserin Trial
Wednesday, 31 Oct 2018 

Oct 31 (Reuters) - ACADIA Pharmaceuticals Inc ::ACADIA PHARMACEUTICALS ANNOUNCES POSITIVE TOP-LINE RESULTS FROM PHASE 2 CLARITY TRIAL OF PIMAVANSERIN FOR ADJUNCTIVE TREATMENT IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER (MDD).ACADIA PHARMACEUTICALS INC - PIMAVANSERIN MET PRIMARY ENDPOINT.ACADIA PHARMACEUTICALS INC - PIMAVANSERIN MET KEY SECONDARY ENDPOINT.ACADIA PHARMACEUTICALS INC - TO INITIATE PHASE 3 PROGRAM IN ADJUNCTIVE MDD IN 1H 2019.ACADIA - POSITIVE RESULTS ALSO OBSERVED ON SEVEN ADDITIONAL SECONDARY ENDPOINTS.  Full Article

Acadia Pharmaceuticals Announces Executive Leadership Change
Tuesday, 30 Oct 2018 

Oct 29 (Reuters) - ACADIA Pharmaceuticals Inc ::ACADIA PHARMACEUTICALS ANNOUNCES EXECUTIVE LEADERSHIP CHANGE.ACADIA PHARMACEUTICALS INC - TODD S. YOUNG, EXECUTIVE VICE PRESIDENT AND CHIEF FINANCIAL OFFICER, WILL BE LEAVING.ACADIA PHARMACEUTICALS INC - ELENA RIDLOFF, CFA, SENIOR VICE PRESIDENT, INVESTOR RELATIONS WILL SERVE AS COMPANY'S INTERIM CHIEF FINANCIAL OFFICER..ACADIA PHARMACEUTICALS INC - TODD YOUNG, CHIEF FINANCIAL OFFICER, WILL BE LEAVING EFFECTIVE OCTOBER 31, 2018 TO JOIN ANOTHER HEALTHCARE COMPANY.  Full Article

FDA Says Finds No New Or Unexpected Safety Risks Associated With Nuplazid
Thursday, 20 Sep 2018 

Sept 20 (Reuters) - U.S. Food and Drug Administration::FDA - FINDS NO NEW/UNEXPECTED SAFETY RISKS ASSOCIATED WITH NUPLAZID, A MEDICATION TO TREAT HALLUCINATIONS, DELUSIONS OF PARKINSON’S DISEASE PSYCHOSIS.FDA- CONCLUSION REMAINS UNCHANGED THAT NUPLAZID'S BENEFITS OUTWEIGH ITS RISKS FOR PATIENTS WITH HALLUCINATIONS&DELUSIONS OF PARKINSON’S DISEASE PSYCHOSIS.FDA - RISK OF QT PROLONGATION AND SERIOUS ARRHYTHMIA ASSOCIATED WITH NUPLAZID IS NOTED IN WARNINGS AND PRECAUTIONS SECTION OF DRUG LABEL.FDA - SOME POTENTIALLY CONCERNING PRESCRIBING PATTERNS WERE OBSERVED ASSOCIATED WITH NUPLAZID.  Full Article

Acadia Pharmaceuticals Q2 Loss Per Share $0.51
Thursday, 9 Aug 2018 

Aug 8 (Reuters) - ACADIA Pharmaceuticals Inc ::ACADIA PHARMACEUTICALS REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS.Q2 LOSS PER SHARE $0.51.Q2 SALES $57.1 MILLION VERSUS I/B/E/S VIEW $58.6 MILLION.Q2 EARNINGS PER SHARE VIEW $-0.45 -- THOMSON REUTERS I/B/E/S.LOWERING ITS 2018 NUPLAZID NET SALES GUIDANCE TO BE BETWEEN $210 MILLION AND $225 MILLION.FOR Q3 OF 2018, ACADIA EXPECTS NUPLAZID NET SALES TO BE BETWEEN $52 MILLION AND $59 MILLION.ACADIA PHARMACEUTICALS - LOWERING GUIDANCE FOR ITS YEAR END 2018 CASH, CASH EQUIVALENTS AND INVESTMENT SECURITIES TO BE BETWEEN $155 MILLION TO $170 MILLION.  Full Article

Acadia Pharmaceuticals posts Q3 loss of $0.53 per share
Wednesday, 8 Nov 2017 

Nov 7 (Reuters) - Acadia Pharmaceuticals Inc :Acadia Pharmaceuticals reports third quarter 2017 financial results.Q3 loss per share $0.53.Q3 sales $35.6 million versus I/B/E/S view $32 million.Sees FY 2017 sales $124 million to $127 million.Q3 earnings per share view $-0.62 -- Thomson Reuters I/B/E/S.  Full Article

Acadia's schizophrenia treatment misses late-stage main goal; shares fall 16%

Acadia Pharmaceuticals Inc said on Monday its add-on treatment for schizophrenia failed to meet the main goal in a late-stage study.